News

Sensitisation to pollen in population groups

October 2022

An interesting epidemiological study has been published in the Journal of Asthma and Allergy on pollen sensitisation profiles in a population with identical exposure but different origins in order to assess the influence of environmental and ancestral factors. The study was carried out in a town in Murcia (Spain) on the resident population of Spanish and Moroccan origin.
More info

ALXOID-mites in WAO Journal

September 2022

A study conducted in Colombia to evaluate immunotherapy to house dust mites, including Blomia tropicalis, has been published in WAOJ (World Allergy Organization Journal). The study has assessed the efficacy and safety of ALXOID of three mites in a prospective trial with 250 patients led by Dr. Cardona (University of Antioquia) with the collaboration of INMUNOTEK.
More info

Phase 2 trial with mannan-HDM allergoids published

Conjugados alergoidesMay 2022

Allergy publishes the results of the first-in-human clinical trial (Phase 2) aimed at addressing the safety and optimal dose of the new mannan-house dust mite allergoid vaccines for subcutaneous and sublingual immunotherapy. The study, conducted in the Mediterranean coast of Spain and coordinated by Dr. Antonio Nieto as principal investigator, involved 13 allergy centers and 196 patients.
More info

Editorial in NEJM Evidence on MV140

March 2022

NEJM Evidence highlights in an Editorial the results of the clinical trial with MV140 recently published in that journal. MV140 showed its safety and efficacy in a randomized, double-blind, placebo-controlled, Phase 3 trial conducted in Spain and the United Kingdom.
More info

Cost-Effectiveness with MV140 (UROMUNE)

February 2022

The reduction of recurrent urinary tract infections after treatment with MV140 (UROMUNE) represents a significant health saving according to a study published in Urologia Internationalis. The savings have been calculated taking into account the healthcare costs and medication associated with this type of infection in Spain. This study was carried out at the Urology Department of the Albacete University Hospital Complex.
More info

MV140 clinical trial results (phase 3) published

January 2022

The results obtained with MV140 in women with recurrent urinary tract infections (UTIs) have been published in NEJM_Evidence. This is a randomized, placebo-controlled, Phase 3 clinical trial conducted in Spain and the United Kingdom to evaluate the safety and efficacy of MV140 in this condition.
More info

MV130 confers protection by inducing trained immunity

January 2022

Results published in Cell Reports show that MV130 protects against respiratory viral infections by inducing Trained Immunity. This type of immunity generates memory and depends on the "training" of Innate Immune System cells. Trained immunity involves epigenetic and metabolic changes that make trained cells more effective against infections, including viral infections.
More info

MV130 protects and boosts vaccines against SARS-CoV-2

November 2021

According to the results published in Frontiers in Immunology, MV130 protects against experimental infection with SARS-CoV-2 in hACE2 transgenic mice. In addition, pretreatment with MV130 is shown to enhance the immunogenicity of candidate COVID-19 vaccines directed against viral protein S, enhancing both antibody and cell-specific responses.
More info

Allergoid-mannan conjugates on macrophages

Conjugados alergoidesOctober 2021

Allergy publishes a study showing that allergoid-mannan conjugates confer tolerogenic properties to human macrophages. These cells have been described to play a relevant role in the induction of allergen-specific tolerance in sublingual immunotherapy models, so this study may help to better understand the immunological mechanisms of allergy vaccines based on these glycoconjugates.
More info

MV140 results in recurrent UTIs

October 2021

The results of a clinical trial with MV140 in women suffering from recurrent urinary tract infections (UTI) have been presented at the ICS21 (International Continence Society) congress, as well as at the BAUS21 (British Association of Urological Surgeon), EAU21 (European Association of Urology) and AUA21 (American Urological Association). The study (phase III) has been carried out in several centers in Spain and the United Kingdom, including 240 patients in the active group and placebo.
More info